<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01663051</url>
  </required_header>
  <id_info>
    <org_study_id>10-018</org_study_id>
    <nct_id>NCT01663051</nct_id>
  </id_info>
  <brief_title>Evaluation of the Zilver® Vena™ Venous Stent</brief_title>
  <acronym>VIVO EU</acronym>
  <official_title>Evaluation of the Zilver® Vena™ Venous Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, non-randomized, multi-center study is intended to evaluate the Zilver®
      Vena™ stent in the treatment of symptomatic iliofemoral venous outflow obstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed via ultrasound</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Iliofemoral Venous Outflow Obstruction</condition>
  <arm_group>
    <arm_group_label>Stent</arm_group_label>
    <description>Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zilver Vena Venous Stent</intervention_name>
    <description>Stenting iliofemoral venous outflow obstruction</description>
    <arm_group_label>Stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic iliofemoral venous outflow obstruction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic venous outflow obstruction in up to two iliofemoral venous segments (one
             in each limb), demonstrated by:

          -  CEAP 'C' ≥ 3, or

          -  VCSS pain score ≥ 2

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  Pregnant or planning to become pregnant in the next 12 months

          -  Planned surgical or interventional procedures (except thrombolysis and thrombectomy
             in preparation for the procedure or vena cava filter placement prior to stent
             implantation in patients at high risk for pulmonary embolism) within 30 days prior to
             or after the study procedure.

          -  Lesions with intended treatment lengths extending into the inferior vena cava or
             below the level of the lesser trochanter

          -  Previous stenting of the target vessel

          -  Iliofemoral venous segment unsuitable for treatment with available sizes of study
             devices
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashley Hughes, MS</last_name>
    <phone>765-463-7537</phone>
    <email>ahughes@medinst.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Stage</last_name>
    <phone>+45 56868686</phone>
    <email>lars.stage@cookmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Galway University Hospitals</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard O'Sullivan, Dr. Med</last_name>
      <phone>+35 3 915 423 56</phone>
      <email>Gerard.osullivan2@hse.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta R. Ortega, Dr. Med</last_name>
      <phone>+34 61 92 07 922</phone>
      <email>pgusanian@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Binkert</last_name>
      <email>christoph.binkert@ksw.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayan Karunanithy</last_name>
      <email>narayan.karunanithy@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
